Biotech M&A on Track for Best Year Since Pre-Covid Era

Biotech mergers and acquisitions are experiencing a strong start in 2026, poised for their best year since before the Covid-19 pandemic, driven by looming patent cliffs, buoyant public markets, and Big Pharma's pipeline expansion efforts.

4 Jun, 05:45 — 4 Jun, 05:45

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual83d ago

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Read full article →

PERSPECTA

PERSPECTA

Biotech M&A on Track for Best Year Since Pre-Covid Era

Sources

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Related Stories

Don’t praise Meta ‘for what the court orders them to do’: Meta will only pay the full $17.1 billion settlement if TikTok and YouTube match it

Hungary's Paks Nuclear Plant Returns to Full Power Output

H.C. Wainwright Upgrades Zymeworks Price Target Following FDA Approval

Meta Agrees to $18 Billion Settlement in Child Social Media Addiction Lawsuits

PERSPECTA